BioCryst Pharmaceuticals Announces Executive and Director Changes
Ticker: BCRX · Form: 8-K · Filed: Jun 4, 2025 · CIK: 882796
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointments
Related Tickers: BCRX
TL;DR
BioCryst's board and exec team are shuffling; new directors in, some execs out.
AI Summary
BioCryst Pharmaceuticals, Inc. announced on May 31, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers.
Why It Matters
Changes in key leadership and director positions can signal shifts in company strategy, governance, or future performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational continuity.
Key Numbers
- 000-23186 — SEC File Number (Identifies the company's filing history with the SEC.)
- 62-1413174 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- May 31, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the departures and appointments?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers,' suggesting broad impact across leadership.
Are there any specific names of departing or newly elected directors/officers mentioned?
This specific 8-K filing does not list the names of the departing or newly elected individuals, but rather categorizes the event.
What is the effective date of these leadership changes?
The earliest event reported is dated May 31, 2025, with the date of change also listed as May 31, 2025.
Does the filing provide details on the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, implying that details regarding these arrangements are included.
What is the primary reason for this 8-K filing?
The primary reason for this 8-K filing is to report significant corporate events including the departure of directors or officers, election of directors, appointment of officers, and changes in compensatory arrangements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).